Steven Hildemann has been named as the new Executive Vice President, Chief Medical Officer and Head of Global Medical Affairs and Pharmacovigilance at French pharma firm, Ipsen.
Prior, Dr. Hildemann held leadership roles in science-based bioethics and built an innovative digital health start-up in cancer care after serving for five years at Merck.
He also held several strategic leadership positions with biopharmaceutical companies such as Pharmacia-Pfizer and Schering-Plough-MSD.
In his new role, he will act as a strategic partner to Ipsen’s scientific, clinical and business teams. He will provide a global medical strategy based on real value to patients and caregivers.
In close partnership with R&D, Dr. Hildemann will lead the generation of post-launch clinical trial data by defining, prioritizing, optimizing or guiding studies in line with this strategy.
As a member of the Executive Leadership team, he will actively contribute to the overall management and strategic leadership of the company.
The appointment is effective March 1.